GMAB ▼ -1.5% - Genmab A/S $GMAB H.C. Wainwright raised the firm's price target on Genmab to $50 from $40 and keeps a Buy rating on the shares. The company announced positive results from the Phase 3 trial evaluating Epkinly plus R-CHOP versus R-CHOP in first-line diffuse large B-cell lymphoma patients, the analyst tells investors in a research note. 07-OCT-2026 08:47 AM ET